Case Report

Neuropsychiatric Lupus and Lupus Nephritis Successfully Treated with Combined IVIG and Rituximab: An Alternative to Standard of Care

Mohamed M. Cheikh,1,2 Abdullah K. Bahakim,3 Moayad K. Aljabri,3 Saad M. Alharthi,2 Sanad M. Alharthi,2 Abdullah K. Alsaeedi,2 and Saad F. Alqahtani2

1Department of Medicine, Fakeeh College for Medicine Science, Jeddah, Saudi Arabia
2Internal Medicine Department, Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
3Department of Medicine and Surgery, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia

Correspondence should be addressed to Abdullah K. Bahakim; ab.bahakeem1101@gmail.com

Received 25 April 2022; Revised 22 July 2022; Accepted 13 August 2022; Published 28 August 2022

1. Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with unpredictable course and flares. The clinical manifestation can vary from mild to severe and life-threatening disease. Infection is the primary cause of mortality in hospitalized SLE patients. There is a paucity of evidence to support the co-management of SLE with major organ involvement and sepsis. We describe the clinical response of a 35-year-old male diagnosed with SLE; then, he developed severe sepsis and a flare of SLE with major organ involvement including lupus nephritis (LN), myocarditis, and neuropsychiatric systemic lupus erythematosus (NPSLE). Based on the patient’s condition, a treatment dilemma was encountered, and after a multidisciplinary meeting, the decision was made to use a combination of rituximab (RTX), intravenous immunoglobulin (IVIG), and pulse steroid. Shortly, the patient’s condition started to improve, and his symptoms were resolved. In conclusion, our clinical case suggests that combined RTX, IVIG, and pulse steroid seem to be effective and safe in achieving clinical response, thus representing a good choice for managing severe SLE flares in sepsis.
intravenous cyclophosphamide (CYC) is the standard
treatment for NPSL, LN, and lupus myocarditis [8, 9]. In-
fection is the leading cause of death in hospitalized SLE
patients; the risk of infection is associated with high disease
activity, renal involvement, leucopenia, thrombocytopenia,
and treatment with high-dose GC and IS agents [8, 10].
Treating a patient with a flare of autoimmune diseases like
SLE and sepsis might be challenging. Here we present a case
of SLE with involvement of three major organs in the context
of infective endocarditis and sepsis that were successfully
treated with pulse steroid, rituximab (RTX), and intravenous
immunoglobulin (IVIG).

2. Case Presentation
A 35-year-old black race male with a past medical history of
hypertension and cardiomypathy presented on 29 June
2021 to the outpatient department (OPD) with fatigability,
weight loss of more than 10 kg over 1 year, subjective fever,
night sweat, anorexia, malaise, oral ulcer, body aches, and no
evidence of arthritis. On examination, mildly elevated blood
pressure, marked proximal and distal muscle weakness,
and enlargement of the subclavian and cervical lymph nodes
were noted. Initial laboratory test result showed normocytic
normochromic anemia, positive antinuclear antibody
(ANA) 262.2 (by ELISA technique), anti-SM antibody
693.50 CU, anti-ribonuclear protein 643.8 CU, C3 0.13 g/l,
and C4 0.01 g/l. Computed tomography (CT) scan of the
chest, abdomen, and pelvis with intravenous (IV) contrast
was obtained and showed enlarged lymph node groups
above and below the diaphragm associated with hep-
atosplenomegaly. The patient was admitted, and an axillary
excisional lymph node biopsy was done. The initial report
was suggestive of follicular and paracortical hyperplasia. Due
to the severity of his severe constitutional symptoms and
multiple lymph node enlargements, which might be asso-
ciated with lymphoma, the biopsy was sent for a second
opinion which came back with negative findings of lym-
phoma and confirmed a benign finding that includes fol-
licular and paracortical hyperplasia. The diagnosis of SLE
was established based on the Systemic Lupus International
Collaborating Clinics (SLICC) criteria (oral ulcer, positive
ANA, anti-Ds-DNA, anti-SM antibody, and low C3). The
patient was started on prednisolone 30 milligrams (mg) daily
and hydroxychloroquine (HCQ) 400 mg daily and dis-
charged home.

After six days, the patient presented to the emergency
room with severe musculoskeletal (MSK) manifestations
(arthritis of both wrists, elbow, metacarpophalangeal (MCP)
joints, proximal interphalangeal (PIP) joints, and knee
joint). He was admitted to the floor based on his MSK
symptoms and started on intravenous 1 mg/kg of methyl-
prednisolone and painkillers. The patient also had cardio-
myopathy manifestations in the form of exertional dyspnea
and lower limb edema, which was confirmed with an
echocardiogram (ECHO) that showed mild systolic dys-
function (ejection fraction of 45–50%). The ECHO findings
upon admission were similar to the previous baseline ECHO
that was done six months prior to this presentation.

During admission, the patient started to show signs of
ongoing sepsis in the form of frequent spikes of high-grade
fever and an increase in leukocytes (17.53 × 10³/μl) and
C-reactive protein (232.70 mg/L). He was started on broad-
spectrum antibiotics, and septic screen that includes cultures
of blood, urine, and sputum, chest X-ray, and knee joint
aspiration was done. The blood culture showed persistent
Gram-negative Salmonella non-Typhi and MSSA bacter-
emia for three days, and the source of MSSA bacteremia was
most likely septic arthritis due to the growth of MSSA in the
synovial fluid culture (Parm resize(1), pos(50,50), size(200,200), bgcol(156))
necessitating admission to the intensive care unit (ICU) for vasopressors and mechanical ventilation. Continuous renal replacement therapy (CRRT) was
introduced after the deterioration in the patient renal
condition and he became anuric; the urine albumin to
creatinine ratio was 1560 mg/g. Although his AKI was
multifactorial, including contrast nephropathy, sepsis, and
possible glomerulonephritis, a kidney biopsy was taken to
rule out lupus nephritis. The biopsy showed diffuse global
lupus nephritis with active lesion class IV.

Transthoracic echocardiogram (TTE) and trans-
esophageal echocardiogram (TEE) did not show definitive
valve vegetation, and CT pulmonary angiography was done
and it ruled out pulmonary embolism; however, it showed
right lower lobe nodular consolidation. Three days later, CT
abdomen and pelvis with contrast was done, and it showed
no evidence of bowel perforation and slight regression of the
right lower lobe nodular consolidations with new central
cavitation was noted; findings suggest infectious process/
septic emboli. The patient was seen by infectious disease (ID)
team, and according to Duke criteria for infective endo-
carditis (IE), the patient met one major criteria (typical
organism from 2 separate blood cultures, persistently pos-
itive blood cultures drawn >12 hours apart) and two minor
criteria (findings of infectious process/septic emboli and
fever). An ophthalmology examination showed no Roth
The patient was started on meropenem 1 g IV three times a day (TID) for eight weeks, covering Salmonella and MSSA.

A week later, the patient started to recover from his septic shock, he was extubated, and his blood pressure was stabilized without vasopressors. However, he developed new symptoms; he was found to have an acute change in his mental status in the form of visual hallucination, confusion, elated mood, and disorientation to the time and place. Magnetic resonance imaging (MRI) of the brain with contrast showed bilateral deep white matter enhancement (Figures 1 and 2). Lumbar puncture (LP) was done to exclude infectious causes with film array meningitis panel and culture, which were negative. However, he had albuminocytological dissociation, high cerebrospinal fluid (CSF) protein (113.5 mg/dl), and IgG without pleocytosis, which indicated an intracranial inflammatory process. The patient was diagnosed with neuropsychiatric manifestations of lupus; this was supported by very active serology with an anti-dsDNA antibody of more than 669 IU/ml and very low C3 and C4 complement despite high doses of methylprednisolone 1 mg/kg on the preceding seven days. The patient also had a drop in his ejection fraction from 40% to 30%, with high troponin suggesting myocarditis.

Cyclophosphamide was not given because the patient was recovering from severe sepsis that required ICU admission, vasopressors, and intubations. However, weighing risks and benefits and after a multidisciplinary meeting with ICU, infectious disease, rheumatology, and nephrology teams, the decision was made to give him a combined IVIG of 0.4 g/kg/day for five days and RTX 500 mg once with pulse steroid therapy 1 g/day for five days. This regimen was started after seven days of the first negative blood culture.

After five days, the patient’s condition started to improve. The patient’s hallucinations subsided, and he was oriented and less confused with intact short-term and long-term memory. The clinical improvement was accompanied by improvement of biochemical markers and other indicators of the severity of the patient’s condition. Anti-dsDNA upon admission was >666.90 IU/ml and then declined to 55.3 IU/ml, and C3 and C4 upon admission were (0.13, 0.01) g/l and then increased to (0.79, 0.16) g/l, respectively (Table 1).

Three weeks later, the patient was started on mycophenolic acid (MMF) 500 mg gradually to be increased to 1 g twice a day (BID) besides 1 mg/kg prednisolone for four weeks and then tapered down with a reduction of 10 mg per week and hydroxychloroquine (HCQ) 400 mg in order to maintain this remission and control other system manifestations.

After four months, there was a marked improvement in his MSK manifestations and neuropsychiatric symptoms (cognitive and conscious levels improved). Regarding lupus nephritis, he achieved complete remission (albumin to creatinine ratio decreased from 1560 to 150). In order to achieve full disease control, he was given belimumab 200 mg subcutaneously every week. In addition, his decompensated heart failure symptoms improved, and his repeated TTE showed that his ejection fraction is back to the baseline of 40%. He is taking anti-failure therapy, including angiotensin-converting enzyme inhibitors (ACE-I) and beta-blockers, and continuing HCQ 400 mg, double-strength tablet trimethoprim 160, sulfamethoxazole 800 mg for pneumocystis pneumonia prophylaxis, and prednisone 10 mg/week.
3. Discussion

In this case report, a challenging clinical scenario was encountered. First, our patient was diagnosed with SLE; then, he developed severe sepsis and a flare of SLE with major organ involvement (LN, NPSLE, and myocarditis).

The substantial immune dysfunction among patients with SLE makes them more susceptible to infection. Both disease activity and therapy play a crucial role in infection development. Infections can be confusing to distinguish from disease flare-ups in SLE patients. The death rate in SLE patients with infection is five times higher than the general population. Growing literature evidence highlights the pivotal role of infections in the exacerbation of SLE [11].

The treatment option depends on existing disease manifestations, patient age, safety concerns, and cost. Currently, hydroxychloroquine is considered mandatory in managing SLE and is recommended throughout the entire course of the disease. Furthermore, glucocorticoids (GCs) provide the most immediate anti-inflammatory impact of all immunosuppressive treatments and are considered the most widely utilized therapy to manage mild-severe flares of SLE [12]. Even more critical, cyclophosphamide (CYC) is used in organ-threatening diseases (specifically renal, neuropsychiatric, or cardiopulmonary) and only as a rescue treatment in refractory non-major organ involvements. Also, it is imperative to highlight the risk of CYC therapy use during infections [8].

Our patient came with sepsis and a flare of SLE with involvement of three major organs, which was a puzzling scenario due to the lack of formal guidelines for co-management of sepsis and involvement of three major organs. In our opinion, since there is no evidence to support one over the other regimen in such a case, a combination of RTX, IVIG, and pulse steroid administrated was well tolerated in our patient and may be a better decision due to its better side effect profile; nevertheless, this management plan must be taken based on experts’ opinion.

Nowadays, RTX is solely used off-label in SLE patients with severe renal or extrarenal disease refractory to other IS agents or contraindications to these drugs [8]. While giving IVIGs in SLE patients has inadequate evidence for their efficacy and is derived from case reports and case series, existing indications suggested IVIGs in SLE for severe cases not responding to conventional immunosuppressive agents, patients with active SLE, and concomitant infection [1].

Throughout the literature review, we found various cases reported RTX and IVIGs. This combination showed efficacy and safe therapeutic response in managing complicated SLE. To begin with, a 41-year-old Caucasian male with a history of SLE had myocarditis; then, he developed refractory cardiogenic shock treated with RTX, IVIG, and pulse steroid administrated was well tolerated in our patient and may be a better decision due to its better side effect profile; nevertheless, this management plan must be taken based on experts’ opinion.

Table 1: Laboratory data through the course.

| Variable                        | On presentation to the OPD | During sepsis | After combined rituximab and IVIG | Reference range |
|---------------------------------|---------------------------|--------------|----------------------------------|-----------------|
| WBC count (10³/µl)             | 3.84                      | 17.53        | 4.90                             | 4.5–11          |
| Deferential count               |                           |              |                                  |                 |
| Neutrophils (%)                 | 51.30                     | 91.50        | 46.50                            | 35–80           |
| Lymphocytes (%)                 | 42.70                     | 5.00         | 39.00                            | 24–44           |
| Monocytes (%)                   | 4.20                      | 3.20         | 12.90                            | 4.7–12.5        |
| Eosinophils (%)                 | 1.80                      | 0.10         | 1.40                             | 0–4             |
| Basophils (%)                   | 0.00                      | 0.20         | 0.20                             | 0–1             |
| RBC count (10⁶/µl)             | 3.28                      | 3.67         | 5.73                             | 4.3–5.7         |
| Hemoglobin (g/dl)               | 8.50                      | 10.10        | 14.60                            | 13.2–17.3       |
| Hematocrit (%)                  | 28.20                     | 31.40        | 45.00                            | 39–49           |
| MCV (fl)                        | 86.00                     | 85.60        | 78.50                            | 80–100          |
| MCH (pg)                        | 26.00                     | 27.50        | 25.50                            | 26–34           |
| MCHC (g/dl)                     | 30.10                     | 32.20        | 32.40                            | 32–36           |
| RDW (%)                         | 16.30                     | 15.60        | 15.20                            | 11.6–14.6       |
| Platelet count (10⁵/µl)         | 351.00                    | 261.00       | 241.00                           | 150–440         |
| C-reactive protein (mg/L)       | 5.33                      | 232.70       | —                                 | 0–3.0           |
| Antinuclear antibodies          | 262.20                    | —            | —                                 | <20             |
| Anti-Smith antibody (CU)        | >693.50                   | —            | —                                 | <20             |
| Anti-ribonuclear protein (CU)   | >643.80                   | —            | —                                 | <20             |
| Anti-SCL-70 (unit)              | 35.90                     | —            | —                                 | <20             |
| Anti-dsDNA antibodies (IU/ml)   | >666.90                   | >666.90      | 55.30                            | <27             |
| Complement 3 (g/l)              | 0.13                      | 0.40         | 0.79                             | 0.9–1.8         |
| Complement 4 (g/l)              | 0.01                      | 0.06         | 0.16                             | 0.1–0.4         |
| Creatinine (mg/dl)              | 0.76                      | 2.27         | 0.83                             | 0.67–1.17       |
| Creatinine kinase (U/l)         | 630.00                    | 36.00        | —                                 | 39–308          |
| Protein/creatinine ratio (mg/g) | 373.72                    | —            | 144.02                           | <200            |
| Albumin/creatinine ratio (mg/g) | —                        | 1560.84      | —                                 | —               |
| Protein (CSF) (mg/dl)           | —                        | 113.50       | —                                 | 15–45           |
| Glucose (CSF) (mg/dl)           | —                        | 45.50        | —                                 | 40–70           |
| Total leukocytes (CSF) (/MicroL) | —                        | 4.00         | —                                 | —               |
respond to standard treatment and consequently received RTX and IVIG successfully [14]. Moreover, Costa et al. demonstrated a clinical case of a 32-year-old woman with lupus and fever of unknown origin, who developed unusual complications, including visceral leishmaniasis, macrophage activation syndrome (MAS), and DAH that was started on RTX, IVIG, and steroid and reported a good response [15].

In addition to previous cases, a case of a 35-year-old woman with SLE who developed hypoprothrombinemia-lupus anticoagulant syndrome achieved a sustained remission following treatment with RTX, IVIG, and prednisolone [16]. Lastly, a 64-year-old man presented with relapsed NPSLE, and a combination of IVIG and RTX was started. Consequently, his neuropsychiatric symptoms subsided, and hisserological testing revealed decreased disease activity [17].

In conclusion, our clinical case suggests that the RTX, IVIG, and pulse steroid combination therapeutic scheme appears to be safe and successful in achieving a clinically significant response, thus representing a good choice for treating severe SLE manifestations in sepsis including LN, NPSLE, and myocarditis. Of course, it would be hard to attribute the response to one agent more than the others, but this strategy effectively reduced inflammation and prevented imminent death. Furthermore, to our knowledge, this is the first case with this dilemma in treatment that was successfully treated.

Data Availability

No data were used to support this study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] K. T. El Hadidi, B. M. Medhat, N. M. Abdel Baki et al., “Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center,” Lupus, vol. 27, no. 6, pp. 1030–1038, 2018.
[2] D. Nikolopoulou, M. Kostopoulou, A. Pieta et al., “Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ‘attikon’ cohort,” Lupus, vol. 29, no. 5, pp. 514–522, 2022.
[3] M. Rahman, S. B. Sayeed, R. Hassan et al., “Patterns of organ involvement and outcomes of SLE: a real-life experience in,” Lupus Clinics, vol. 21, no. 2, p. 5, 2020.
[4] H. L. Matthew, C. Michael, C. Sang et al., “The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes,” Arthritis & Rheumatism, vol. 42, no. 4, pp. 599–608, 1999.
[5] H.-J. Anders, R. Saxena, M. Zhao, I. Parodis, J. E. Salmon, and C. Mohan, Lupus nephritis. Nat Rev Dis Primer, vol. 6, no. 1, pp. 1–25, 2020.
[6] C.-R. Wang, Y. S. Tsi, and W. T. Li, “Lupus myocarditis receiving the rituximab therapy—a monocentric retrospective study,” Clinical Rheumatology, vol. 37, no. 6, pp. 1701–1707, 2018.
[7] K. G. Moder, T. D. Miller, and H. D. Tazelaar, “Cardiac involvement in systemic lupus erythematosus,” Mayo Clinic Proceedings, vol. 74, no. 3, pp. 275–284, 1999.
[8] A. Fanouriakis, M. Kostopoulou, A. Alunno et al., “2019 update of the EULAR recommendations for the management of systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 78, no. 6, pp. 736–745, 2019.
[9] G. Thomas, F. Cohen Aubart, L. Chiche et al., “Lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients,” Journal of Rheumatology, vol. 44, no. 1, pp. 24–32, 2017.
[10] D. Chen, J. Xie, H. Chen et al., “Infection in Southern Chinese patients with systemic lupus erythematosus: spectrum, drug resistance, outcomes, and risk factors,” Journal of Rheumatology, vol. 43, no. 9, pp. 1650–1656, 2016.
[11] L. Oud, “Epidemiology and outcomes of sepsis among hospitalizations with systemic lupus erythematosus admitted to the ICU: a population-based cohort study,” Journal of Intensive Care Medicine, vol. 8, no. 1, p. 3, 2020.
[12] C. Magro-Checa, E. J. Zirkzee, T. W. Huizinga, and G. M. Steup-Beekman, “Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives,” Drugs, vol. 76, no. 4, pp. 459–483, 2016.
[13] S. Tariq, A. Garg, A. Gass, and W. S. Aronow, “Myocarditis due to systemic lupus erythematosus associated with cardiogenic shock,” Archives of Medical Science, vol. 14, no. 2, pp. 460–462, 2018.
[14] A. Prior-Español, M. Martínez-Morillo, A. Riveros-Frutos, and A. Olivé, “Tratamiento con rituximab e inmunoglobulinas en la hemorragia alveolar difusa recurrente en lupus eritematoso sistémico,” Medicina Clinica, vol. 145, no. 11, pp. 507–508, 2015.
[15] A. Costa, C. Pais, S. Cerqueira, and F. Salvador, “Vascular leishmaniasis associated with macrophage activation syndrome and diffuse alveolar hemorrhage in a lupus patient,” Acta Medica Portuguesa, vol. 31, no. 10, pp. 593–596, 2018.
[16] R. D. Paschal and A. T. Neff, “Resolution of Hypoprothrombinemia-Lupus Anticoagulant Syndrome (HILAS) after multidrug therapy with rituximab: a case report and review of the literature,” Haemophilia, vol. 19, no. 2, pp. e62–e65, 2013.
[17] E. Watson, S. Minehan, and R. White, “It’s never lupus . . . until it is: Primary neuropsychiatric systemic lupus erythematosus presenting as psychosis treated with intravenous immunoglobulin and rituximab; a case study. (P6.191),” Neurology, vol. 88, no. 16, p. P6.191, 2017.